Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer

被引：17

作者：

Bhatt A. ^{[1
]}

Goéré D. ^{[2
]}

机构：

[1] Department of Surgical Oncology, Fortis Hospital, 154/9 Bannerghatta road, Opposite IIM-Bangalore, Bangalore

[2] Department of Surgical Oncology, Gustave Roussy, Cancer Campus, Villejuif

来源：

Indian Journal of Surgical Oncology | 2016年 / 7卷 / 2期

关键词：

Colorectal Cancer; Cytoreductive surgery; HIPEC; Peritoneal Metastases;

D O I：

10.1007/s13193-016-0499-z

中图分类号：

学科分类号：

摘要：

Occurring either synchronously or metachronously to the primary tumor, peritoneal metastases (PM) are diagnosed in 8 to 20 % of the patients with colorectal cancer (CRC). Prognosis of these patients appears to be worse than those with other sites of metastases. While systemic therapy has shown significant prolongation of survival in patients with stage IV colorectal cancer, the outcomes in the subset of patients with PM has been much inferior. Over the last 2 decades, cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) have been effective in substantially prolonging survival in patients with colorectal PM and have the potential to cure certain patients as well. This article reviews the current evidence for CRS and HIPEC to treat colorectal PM as well as future research going on in this form of locoregional treatment. © 2016, Indian Association of Surgical Oncology.

引用

页码：177 / 187

页数：10

共 85 条

[1]

Lemmens V.E., Klaver Y.L., Verwaal V.J., Rutten H.J., Coebergh J.W.W., De Hingh I.H., Predictors and survival of synchronous peritoneal carcinomatoses of colorectal origin: a population-based study, Int J Cancer, 128, 11, pp. 2717-2725, (2011)

[2]

Jayne D.G., Fook S., Loi C., Seow-Choen F., Peritoneal carcinomatosis from colorectal cancer, Br J Surg, 89, 12, pp. 1545-1550, (2002)

[3]

Sadeghi B., Arvieux C., Glehen O., Et al., Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study, Cancer, 88, 2, pp. 358-363, (2000)

[4]

Zerhouni S., McCart A (2012) Peritoneal carcinomatosis of colorectal origin: Is there a role for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?, Oncology Exchange, 11, 2, (2012)

[5]

Gustavsson B., Carlsson G., Machover D., Petrelli P., Roth A., Schmoll H., Tveit K., Gibson F., A review of the evolution of systemic chemotherapy in the Management Of Colorectal Cancer, Clin Colorectal Cancer, 14, 1, pp. 1-10, (2015)

[6]

Chua T.C., Morris D.L., Saxena A., Et al., Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study, Ann Surg Oncol, 18, pp. 1560-1567, (2011)

[7]

Sugarbaker P.H., van tinteren H., Sv R., Et al., Re:Toxicity of Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy, J Surg Oncol, 88, pp. 276-278, (2004)

[8]

Maggiori L., Elias D., Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends, Eur J Surg Oncol, 36, pp. 599-603, (2010)

[9]

Van Gestel Y.R., Thomassen I., Lemmens V.E., Pruijt J.F., van Herk-Sukel M.P., Rutten H.J., Creemers G.J., de Hingh I.H., Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer, Eur J Surg Oncol, 40, pp. 963-969, (2014)

[10]

Segelman J., Granath F., Holm T., Machado M., Mahteme H., Martling A., Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer, Br J Surg, 99, pp. 699-705, (2012)

← 1 2 3 4 5 6 7 8 9 →